Mylan (NSDQ:MYL) and Pfizer (NYSE:PFE) recently announced that the U.S. Federal Trade Commission had signed off on the proposed merger of Mylan and Pfizer’s biopharmaceutical-focused Upjohn brand. Upjohn also includes Pfizer’s Greenstone generic-drug unit. It also owns the rights to Lipitor and Xanax. Pfizer plans to spin out Upjohn on Nov. 13. If all goes…